Abdelrahman Abdelmoneim Sadek Hassan
|
POSITION
TEACHING ASSISTANT AT THE DEPARTMENT OF
PHARMACEUTICS AND INDUSTRIAL PHARMACY
[2018 – Current]
Faculty of Pharmacy, Beni-Suef University
Beni-Suef, Egypt
EDUCATION
MASTER OF DEVELOPMENT OF DRUGS AND HEALTH PRODUCTS [2022 – 2024]
Faculty of Pharmacy,
Paris-Saclay University, Paris, France.
MASTER OF PHARMACEUTICAL SCIENCES [PHARMACEUTICS] [2018 – 2022]
Faculty of
Pharmacy, Beni-suef University, Beni-Suef, Egypt (GPA 3.67/4)
BACHELOR OF PHARMACY (CLINICAL PHARMACY) [2012 – 2017]
Faculty of Pharmacy, Beni-suef
University, Beni-Suef, Egypt (GPA 3.97/4)
PUBLICATION
Salem,
H.F., Ali, A.A., Hegazy, A.M., Sadek, A.R.A. and Aboud, H.M., 2022. Harnessing
of Doxylamine Succinate/Pyridoxine Hydrochloride-Dual Laden Bilosomes as a
Novel Combinatorial Nanoparadigm for Intranasal Delivery: In Vitro Optimization
and In Vivo Pharmacokinetic Appraisal. Journal of Pharmaceutical
Sciences, 111(3), pp.794-809.
INTERNSHIP
Introduction
to International Cooperation Internship
by Hiroshima University [02/2022 – 03/2022]
The
course is a part of an international student exchange program between the partner
universities in Africa and Hiroshima University. The Triangular Study Abroad
Program at Hiroshima University was selected as a part of the Inter-University
Exchange Project promoted by the Ministry of Education, Culture, Sports,
Science and Technology, Japan (MEXT).
National University of
Science and Technology Internship Program for International Students (NIPIS) [07/2021 – 08/2021]
The
program promises to deliver a sublime internship experience that not only advances
professional skills of students but also reinforces their academic competence
through its practical applications. The program is
focused on promoting diversity, growth, cultural exchange and opportunities for
all.
Research Internship at the Central
Research Laboratory of the Faculty
of Pharmacy, Beni-Suef University [2019 – 2021]
? Preparation of di?erent nanoparticles to solve the problems associated
with marketed products.
? In vitro and In vivo assessment of the formulated nanoparticulate drug delivery
systems.
? Using di?erent software
for statistical analysis
like SPSS, Design–Expert and Wolfram Mathematica.
Clinical Pharmacy Internship at the Hospital of Beni-Suef
University [03/2016 – 04/2016]
? Collaborate with clinical pharmacists at
different departments.
? Study the vital role of clinical pharmacists in
the health sector.
? Using drug-drug interaction software in
clinical practice like Lexicomp and Medscape
RECOMMENDATIONS
Formulation and Evaluation of Novel Drug Delivery System for Doxylamine Succinate and Pyridoxine Hydrochloride
ABSTRTACT
The present work is concerned with tailoring and appraisal of a novel nano-cargo;
bilosomes (BLS) dual laded with doxylamine succinate (DAS) and pyridoxine hydrochloride
(PDH), the first treatment option against gestational nausea and vomiting, for intranasal delivery.
This bifunctional horizon could surmount constraints of orally-commercialized platforms both in
dosage regimen and pharmacokinetic profile. For accomplishing this purpose, DAS/PDH-BLS
were elaborated embedding phospholipid, sodium cholate and cholesterol applying thin-film
hydration method based on Box-Behnken design. Utilizing Design-Expert® software, the effect
of formulation variables on BLS physicochemical features alongside the optimal formulation
selection were investigated. Then, the optimum DAS/PDH-BLS formulation was incorporated
into a thermally-triggered in situ gelling base. The in vivo pharmacokinetic studies were
scrutinized in rats for intranasal DAS/PDH-BLS in situ gel compared with analogous intranasal
free in situ gel and oral solution. The optimized BLS disclosed particle size of 243.23 nm, ?
potential of -31.33 mV, entrapment efficiency of 59.18 and 41.63%, accumulative % release
within 8 h of 63.30 and 85.52% and accumulative permeated amount over 24 h of 347.92 and
195.4 µg/cm2 for DAS/PDH, respectively. Following intranasal administration of the inspected
BLS in situ gel, pharmacokinetic studies revealed a 1.64- and 2.3-fold increment in the relative
bioavailability of DAS and a 1.7- and 3.73-fold increase for PDH compared to the intranasal free
in situ gel and oral solution, respectively besides significantly extended mean residence times for
both drugs. Thus, the intranasally harnessed DAS/PDH-BLS could be deemed as a competent
hybrid nanoplatform with auspicious pharmacokinetics and tolerability traits.
Keywords: Doxylamine succinate; Pyridoxine hydrochloride; Emesis gravidarum; Intranasal
delivery; Bilosomes; Pharmacokinetics.